Skip to main content
. 2015 Sep 16;21:2757–2766. doi: 10.12659/MSM.895471

Figure 4.

Figure 4

The effects of AMD3100 blockade on peripheral blood chimerism and donor stromal percentage for IB-eBMCs and IB-cBMCs groups. AMD3100 was injected intraperitoneally at 1- or 7-days at 16 mg/kg per mouse for IB-eBMCs (A, B) and IB-cBMCs (C, D) groups. (A, C) The PBMCs chimerism level was assessed at 1-, 6-, 12-, and 18-weeks after BMT. PBMCs chimerism level data for the IB-eBMCs (A) or IB-cBMCs (C) without AMD3100 injection (dashed lines) was taken as the untreated control. All results were represented as Mean ±SD (%), n=6 per group. *, p value of day 1 injection versus untreated control; #, p value of day 7 injection versus untreated control, ns is for not significant. *, #, p<0.05. (B, D). Donor stromal cells percentage in injected and non-injected BM of IB-eBMCs (B) and IB-cBMCs (D) groups with AMD3100 injection at 1 (triangles) or 7 days (quadrilaterals) were analyzed at 18 weeks after BMT as compared with corresponding untreated controls. Each dot is a result of recipient mice and bars are the mean for each group (%).*, p<0.05.